Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by driver mutations in other genes. METHODS: Five hundred and fourteen consecutive patients with NSCLC of all stages were tested...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Oncotarget
Main Authors: Jakobsen, Jan Nyrop, Santoni-Rugiu, Eric, Grauslund, Morten, Melchior, Linea, Sørensen, Jens Benn
Formáid: Artigo
Teanga:Inglês
Foilsithe: Impact Journals LLC 2018
Ábhair:
Research Paper
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995236/
https://ncbi.nlm.nih.gov/pubmed/29899852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25490
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla